Mirum Pharmaceuticals (NASDAQ:MIRM) Insider Sells $670,258.26 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) insider Joanne Quan sold 7,287 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $91.98, for a total value of $670,258.26. Following the transaction, the insider directly owned 18,864 shares of the company’s stock, valued at $1,735,110.72. This trade represents a 27.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Joanne Quan also recently made the following trade(s):

• On Thursday, January 22nd, Joanne Quan sold 1,822 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.33, for a total value of $170,047.26.
• On Tuesday, January 20th, Joanne Quan sold 6,911 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $90.27, for a total value of $623,855.97.

Mirum Pharmaceuticals Trading Down 1.0%

NASDAQ:MIRM opened at $90.72 on Friday. The firm has a market capitalization of $5.47 billion, a P/E ratio of -189.00 and a beta of 0.52. The business has a 50 day simple moving average of $96.51 and a 200 day simple moving average of $81.14. The company has a debt-to-equity ratio of 0.98, a current ratio of 2.67 and a quick ratio of 2.55. Mirum Pharmaceuticals, Inc. has a 12-month low of $36.88 and a 12-month high of $109.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.13). The company had revenue of $148.93 million during the quarter, compared to analyst estimates of $141.78 million. Mirum Pharmaceuticals had a negative return on equity of 8.53% and a negative net margin of 4.48%.Mirum Pharmaceuticals’s quarterly revenue was up 49.8% on a year-over-year basis. During the same period in the prior year, the business earned $1.00 earnings per share. Equities research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Institutional Trading of Mirum Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Cullen Frost Bankers Inc. bought a new position in Mirum Pharmaceuticals during the fourth quarter valued at about $30,000. MCF Advisors LLC grew its holdings in Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after acquiring an additional 185 shares during the period. Eurizon Capital SGR S.p.A. bought a new stake in Mirum Pharmaceuticals in the fourth quarter worth about $32,000. CIBC Private Wealth Group LLC acquired a new stake in Mirum Pharmaceuticals in the 4th quarter valued at about $32,000. Finally, Quantbot Technologies LP acquired a new stake in Mirum Pharmaceuticals in the 3rd quarter valued at about $33,000.

Analysts Set New Price Targets

MIRM has been the topic of a number of analyst reports. HC Wainwright increased their price objective on shares of Mirum Pharmaceuticals from $102.00 to $130.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research report on Thursday, January 22nd. Evercore set a $126.00 price target on shares of Mirum Pharmaceuticals in a research note on Wednesday, March 4th. TD Cowen lifted their price target on Mirum Pharmaceuticals from $115.00 to $117.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Finally, Morgan Stanley boosted their price objective on Mirum Pharmaceuticals from $95.00 to $123.00 and gave the stock an “overweight” rating in a research report on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $117.00.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.